The SYMMETRY study, a randomized phase III trial that determined efficacy of the small-molecule inhibitor Elesclomol, administered alone or in combination with paclitaxel, provided evidence that while the combination of Elesclomol with paclitaxel led to significant progression-free survival (PFS) in patients with normal serum LDH, there was a trend towards worse overall survival (OS) in patients with high serum LDH [15]

The SYMMETRY study, a randomized phase III trial that determined efficacy of the small-molecule inhibitor Elesclomol, administered alone or in combination with paclitaxel, provided evidence…